@article{db0a7e55784b431d9306e1435356fe37,
title = "Depressive disorder moderates the effect of the FTO gene on body mass index",
abstract = "There is evidence that obesity-related disorders are increased among people with depression. Variation in the FTO (fat mass and obesity associated) gene has been shown to contribute to common forms of human obesity. This study aimed to investigate the genetic influence of polymorphisms in FTO in relation to body mass index (BMI) in two independent samples of major depressive disorder (MDD) cases and controls. We analysed 88 polymorphisms in the FTO gene in a clinically ascertained sample of 2442 MDD cases and 809 controls (Radiant Study). In all, 8 of the top 10 single-nucleotide polymorphisms (SNPs) showing the strongest associations with BMI were followed-up in a population-based cohort (PsyCoLaus Study) consisting of 1292 depression cases and 1690 controls. Linear regression analyses of the FTO variants and BMI yielded 10 SNPs significantly associated with increased BMI in the depressive group but not the control group in the Radiant sample. The same pattern was found in the PsyCoLaus sample. We found a significant interaction between genotype and affected status in relation to BMI for seven SNPs in Radiant (P<0.0057), with PsyCoLaus giving supportive evidence for five SNPs (P-values between 0.03 and 0.06), which increased in significance when the data were combined in a meta-analysis. This is the first study investigating FTO and BMI within the context of MDD, and the results indicate that having a history of depression moderates the effect of FTO on BMI. This finding suggests that FTO is involved in the mechanism underlying the association between mood disorders and obesity.",
keywords = "BMI, FTO gene, body mass index, depression, obesity",
author = "M. Rivera and S. Cohen-Woods and K. Kapur and G. Breen and Ng, {M. Y.} and Butler, {A. W.} and N. Craddock and M. Gill and A. Korszun and W. Maier and O. Mors and Owen, {M. J.} and M. Preisig and S. Bergmann and F. Tozzi and J. Rice and M. Rietschel and J. Rucker and A. Schosser and Aitchison, {K. J.} and R. Uher and Craig, {I. W.} and Lewis, {C. M.} and Farmer, {A. E.} and P. McGuffin",
note = "Funding Information: We thank those who agreed to participate in the studies and the many colleagues who contributed to collection and phenotypic characterisation of the clinical samples, to genotyping and to statistical analyses. This study was funded by the Medical Research Council, UK and GlaxoSmithKline (G0701420). The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. This research was supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme. Dr Cohen-Woods and Dr Schosser were both funded by Postdoctoral Fellowships from the National Institute for Health Research (NIHR) specialist Biomedical Research Centre for Mental Health. Dr Rucker is funded by a Research Training Fellowship from the Wellcome Trust. The CoLaus/PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0–105993, #3200B0-118308, 33CSC0-122661) and from GlaxoSmithKline. S Bergmann is grateful for financial support from the Giorgi-Cavaglieri Foundation, the Swiss National Science Foundation (Grant #3100AO-116323/1), the Swiss Institute of Bioinformatics and the European Frame-work Project 6 (through the AnEuploidy and EuroDia projects).",
year = "2012",
month = jun,
doi = "10.1038/mp.2011.45",
language = "English",
volume = "17",
pages = "604--611",
journal = "Molecular Psychiatry",
issn = "1359-4184",
number = "6",
}